TrialJournal of the American Academy of Dermatology2014

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.

Lauren Okon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.